Pyxis Oncology announces Phase 1/2 trials for PYX-201, combining it with KEYTRUDA® to treat advanced solid tumors. Pyxis Oncology, Inc. has announced the initiation of two significant clinical ...
Denali Therapeutics (DNLI) announced the primary analysis of the Phase 1/2 study in 47 participants with Hunter syndrome in the 24-week treatment period and additional long-term follow-up of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback